ACC/AHA Recommendations for Antithrombotic Therapy in Patients With Mechanical Heart Valves:
VKA Therapy
|
- With mechanical aortic valve, VKA therapy with a target INR of 2.5 if no risk factors (atrial fibrillation, prior thromboembolism, left ventricular dysfunction, or hypercoagulable state) are present (Class I recommendation; Level of evidence: B)
|
- VKA therapy with a target INR of 3.0 after:
|
- Mechanical aortic valve replacement if risk factors are present (Class I recommendation; Level of evidence: B)
|
- Mechanical aortic valve replacement with Starr-Edwards or disc valves other than Medtronic Hall if no risk factors are present (Class I recommendation; Level of evidence: B)
|
- Mechanical mitral valve replacement with any type of valve (Class I recommendation; (Level of evidence: B)
|
Antiplatelet Therapy
|
- At a dose of 75 to 100 mg/day in addition to warfarin in all patients with mechanical valves (Class I recommendation; Level of evidence: A)
|
ACC/AHA Recommendations for Antithrombotic Therapy in Patients With Bioprosthetic Heart Valves
VKA Therapy with target INR of 2.5 (range 2.0 to 3.0):
|
- For the first 3 months after bioprosthetic aortic valve replacement (Class IIb recommendation; Level of evidence B)
|
- For the first 3 months after bioprosthetic mitral valve replacement (Class IIa recommendation; Level of evidence C)
|
Antiplatelet Therapy
|
- After bioprosthetic aortic or mitral valve replacement at a dose of 75 to 100 mg/day (Class IIa recommendation; Level of evidence: B)
|
Stay tuned! Sign up with Facebook!
